Skip To Content

Through an integrated medical, pharmacy, claims and legal approach, we deliver insights to help navigate the ever‑changing Medicare Secondary Payer landscape.

Recent blog posts

April 02, 2020 · From the desk of David W. Young
While there are many unknowns, Optum Workers’ Compensation and Auto No-Fault is committed to our customers, claimants and our team members. We remain fully staffed and operational and continue to ensure that the injured person is receiving the right treatment at the right time for the right duration and for the most appropriate cost. Read more...
March 18, 2020 · From the desk of David W. Young
Given the recent developments and extensive news coverage about COVID-19, we understand the heightened concerns of our clients, partners and injured persons. At Optum Workers’ Comp and Auto No-Fault, our top priorities are the health and wellbeing of those we serve and the safety of those who deliver care; and we stand ready to support your needs during these challenging times.  Our dedicated employees have rigorously planned and tested our processes, systems and supply chains for business continuity, resiliency and recovery to do everything possible to support the health of those we are privileged to serve. Read more...
March 04, 2020 · Clinical Connection team
The novel coronavirus (COVID-19), that began to emerge in late 2019, has become an increasing public health concern due to its ease of person-to-person transmission. Read more...
March 03, 2020 · Optum Settlement Solutions
Medications comprise a large proportion of Workers’ Compensation Medicare Set-Aside Arrangements (WCMSAs). And, as the population ages, more claimants will become eligible for Medicare coverage. So, it is important to stay up-to-date on medication costs and how they affect WCMSAs. Read more...
February 27, 2020 · Clinical Connection team
Voltaren Gel 1% (diclofenac sodium topical gel) ― a common medication in workers’ compensation and auto no-fault ― will soon transition from prescription (Rx) to over-the-counter (OTC) status, according to the U.S. Food and Drug Administration (FDA). Read more...
<< Previous      Next >>
Page 2 of 4

Subscribe today to receive our latest blogs, articles and more.

Subscribe now button
Clinical Connection
Policy Matters